Dravet Syndrome Foundation Inc is located in Cherry Hill, NJ. The organization was established in 2010. According to its NTEE Classification (T30) the organization is classified as: Public Foundations, under the broad grouping of Philanthropy, Voluntarism & Grantmaking Foundations and related organizations. As of 12/2022, Dravet Syndrome Foundation Inc employed 7 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Dravet Syndrome Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Dravet Syndrome Foundation Inc generated $2.5m in total revenue. This organization has experienced exceptional growth, as over the past 8 years, it has increased revenue by an average of 12.5% each year . All expenses for the organization totaled $2.0m during the year ending 12/2022. While expenses have increased by 18.4% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Since 2019, Dravet Syndrome Foundation Inc has awarded 18 individual grants totaling $1,656,183. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE MISSION OF THE DRAVET SYNDROME FOUNDATION IS TO AGGRESSIVELY RAISE FUNDS FOR DRAVET SYNDROME & RELATED EPILEPSIES; SUPPORT & FUND RESEARCH; INCREASE AWARENESS; & PROVIDE SUPPORT TO AFFECTED INDIVIDUALS & FAMILIES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
DSF FUNDS RESEARCH FOR BETTER TREATMENTS AND A CURE FOR DRAVET SYNDROME AND RELATED EPILEPSIES BY AWARDING RESEARCH GRANTS TO QUALIFIED SCIENTISTS AND CLINICIANS. THESE GRANTS FUND INITIAL RESEARCH HYPOTHESES THAT HAVE NOT BEEN FULLY EXPLORED. THE RESULTS EXTRACTED FROM THIS TYPE OF RESEARCH WILL HELP BRING UNTESTED RESEARCH TO THE POINT THAT IT CAN QUALIFY FOR LARGER GOVERNMENTAL FUNDING. SINCE 2009, DSF HAS AWARDED OVER $6.4 MILLION TO 56 RESEARCH ENDEAVORS. RESEARCH AREAS INCLUDE SUDEP, GENE THERAPY, DRUG DISCOVERY, SCREENING, TREATMENTS, GENETICS, EPIDEMIOLOGY AND NEURONAL NETWORKS. IN 2020, DSF HIRED A SCIENTIFIC DIRECTOR TO SERVE AS THE LIAISON BETWEEN THE MEDICAL/SCIENTIFIC COMMUNITY AND DSF, DEVELOPING STRATEGIES TO SUPPORT RESEARCH, MANAGE DSF'S INVOLVEMENT IN PROJECTS, AND MOVE PROJECTS FORWARD WITH ASSISTANCE IN PROJECT MANAGEMENT, MANUSCRIPT PREPARATION, AND OTHER WRITING OPPORTUNITIES. THE SCIENTIFIC DIRECTOR ACTS AS A REPRESENTATIVE OF DSF TO OTHER INSTITUTIONS INCLUDING NIH, PDA, PHARMA AND BIOTECHNOLOGY COMPANIES.
RECEIVING A DIAGNOSIS OF DRAVET SYNDROME (DS) CAN BE OVERWHELMING AND MAY LEAVE A FAMILY WITH MANY UNANSWERED QUESTIONS. DSF PRODUCES A BIENNIAL PROFESSIONAL AND FAMILY CONFERENCE DESIGNED TO UNITE COMMUNITY STAKEHOLDERS TO ADDRESS THESE QUESTIONS - FAMILIES, CAREGIVERS, CLINICIANS, RESEARCHERS, AND OTHER PROFESSIONALS. OUR 2022 CONFERENCE WELCOMED OVER 300 PARENTS, CHILDREN AND PROFESSIONALS. THE 3-DAY EVENT FEATURED OVER 30 SPEAKERS WHO PRESENTED ON CURRENT RESEARCH, CO-MORBIDITIES, BEST CARE PRACTICES, AND DAILY LIVING CHALLENGES. IN 2017 THE DSF FAMILY NETWORK WAS ESTABLISHED TO PROVIDE REGIONAL SUPPORT TO FAMILIES. AS PART OF THIS INITIATIVE, 5 EDUCATIONAL WORKSHOPS ARE HELD ACROSS THE COUNTRY ON ODD-NUMBERED YEARS, OPPOSITE OF OUR BIENNIAL CONFERENCE. THESE WORKSHOPS ARE A TIME FOR PATIENTS AND THEIR FAMILIES TO COME TOGETHER TO LEARN ABOUT RESEARCH AND TREATMENT OPTIONS, CONNECT WITH OTHERS IN THEIR REGION, AND BE A PART OF DSF'S SHARED VISION FOR A BETTER OUTCOME FOR THOSE AFFECTED BY DS. IN ADDITION TO THESE CONFERENCES AND WORKSHOPS, DSF HAS ESTABLISHED AN INTERNATIONAL PATIENT ASSISTANCE GRANT PROGRAM TO HELP PATIENTS RECEIVE MEDICAL EQUIPMENT, THERAPY DEVICES, AND EDUCATION AIDES ASSOCIATED WITH DS THAT ARE NOT COVERED THROUGH PRIVATE INSURANCE OR OTHER ASSISTANCE PROGRAMS. SINCE 2009, DSF HAS AWARDED OVER $222K IN ASSISTANCE TO FAMILIES. ON FEBRUARY 3, 2022, DSF HELD AN EXTERNALLY-LED PATIENT-FOCUSED DRUG DEVELOPMENT MEETING ON DS. THIS MEETING WAS A LONG-AWAITED OPPORTUNITY FOR OUR PATIENT COMMUNITY TO EDUCATE REPRESENTATIVES OF THE FDA AND PHARMACEUTICAL COMPANIES, AS WELL AS ACADEMIC RESEARCHERS AND CLINICIANS, ABOUT THE CHALLENGES THAT INDIVIDUALS LIVING WITH DS FACE DAILY. OUR OBJECTIVE WAS TO GIVE PATIENT FAMILIES A PLATFORM TO SHARE WHAT IT MEANS TO HAVE A DS DIAGNOSIS, WHICH SYMPTOMS SHOULD BE PRIORITIZED, AND HOW THIS DISEASE IMPACTS THE QUALITY OF LIFE FOR THE PATIENT AND FAMILY SO THAT THE FDA AND PHARMACEUTICAL COMPANIES CAN UNDERSTAND THE PATIENT EXPERIENCE.
DSF PRODUCES AN ANNUAL RESEARCH ROUNDTABLE MEETING TO PROVIDE OPPORTUNITY FOR RESEARCHERS AND CLINICIANS TO COLLABORATE AND DISCUSS BETTER TREATMENT OPTIONS AND A ROADMAP TOWARD A CURE AND HOW TO BEST FACILITATE BOTH. THIS MEETING STARTED IN 2010 AS A BRAINSTORMING SESSION FOR THE FEW RESEARCHERS WORKING ON DRAVET SYNDROME (DS). DSF HOSTED ITS 13TH ANNUAL RESEARCH ROUNDTABLE, AND HAD OUR LARGEST ATTENDANCE YET, WITH OVER 200 PARTICIPANTS. IN 2022, DSF DEVELOPED A PROFESSIONAL EDUCATION VIDEO SERIES TO HIGHLIGHT THE LATEST GUIDELINES IN CLINICAL CARE. THE DEVELOPMENT OF THIS UPDATED PROFESSIONAL EDUCATIONAL SERIES WAS PROMPTED BY THE RECENT PUBLICATION OF THE INTERNATIONAL TREATMENT CONSENSUS ON DIAGNOSIS AND MANAGEMENT OF DRAVET SYNDROME. ALSO IN 2022, DSF INVITED ADULT NEUROLOGISTS WITH AN INTEREST IN LEARNING MORE ABOUT DS TO ATTEND A MEETING FOCUSED SPECIFICALLY ON HOW TO BETTER SUPPORT FAMILIES THROUGH THE TRANSITION FROM PEDIATRIC TO ADULT CARE.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Mary Anne Meskis Executive Director | Officer | 40 | $155,000 |
Veronica Hood Scientific Director | 40 | $151,200 | |
Jamie Cohen Chief Financial Officer | Officer | 40 | $88,560 |
Kate Hintz President | OfficerTrustee | 1 | $0 |
Ted Odlaug PHD Vice President | OfficerTrustee | 1 | $0 |
Tim Wood Past Treasurer | OfficerTrustee | 1 | $0 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $741,106 |
Related organizations | $0 |
Government grants | $0 |
All other contributions, gifts, grants, and similar amounts not included above | $972,121 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $1,713,227 |
Total Program Service Revenue | $662,596 |
Investment income | $88,364 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $51,595 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $2,515,782 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $500,000 |
Grants and other assistance to domestic individuals. | $21,523 |
Grants and other assistance to Foreign Orgs/Individuals | $172,175 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $243,560 |
Compensation of current officers, directors, key employees. | $177,986 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $223,704 |
Pension plan accruals and contributions | $0 |
Other employee benefits | $0 |
Payroll taxes | $36,441 |
Fees for services: Management | $0 |
Fees for services: Legal | $3,174 |
Fees for services: Accounting | $5,800 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $219,667 |
Advertising and promotion | $7,246 |
Office expenses | $44,011 |
Information technology | $29,597 |
Royalties | $0 |
Occupancy | $0 |
Travel | $32,400 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $411,213 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $0 |
Insurance | $5,394 |
All other expenses | $0 |
Total functional expenses | $2,028,839 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $560,961 |
Savings and temporary cash investments | $447,978 |
Pledges and grants receivable | $0 |
Accounts receivable, net | $54,682 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $6,472 |
Prepaid expenses and deferred charges | $11,792 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $5,167,263 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $6,249,148 |
Accounts payable and accrued expenses | $37,308 |
Grants payable | $299,923 |
Deferred revenue | $151,143 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $488,374 |
Net assets without donor restrictions | $5,548,913 |
Net assets with donor restrictions | $211,861 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $6,249,148 |
Over the last fiscal year, Dravet Syndrome Foundation Inc has awarded $500,000 in support to 4 organizations.
Grant Recipient | Amount |
---|---|
Columbus, OH PURPOSE: Targeting Molecular Responses to Seizures in Dravet Syndrome- Dr. Wagnon's work previously identified that the gene Npas4 is reduced in a mouse model of Dravet syndrome. This project hypothesized that restoration of high Npas4 expression could ameliorate seizures and other symptoms using viral-mediated delivery of Npas4 to the brain of mice with SCN1A haploinsufficiency. | $150,000 |
Saint Louis, MO PURPOSE: Ketogenic Diet Modulated Brain Energy Metabolism in Dravet Syndrome- Dr. Thio and Dr. Garbow work together on this collaborative project to better understand the mechanisms whereby the ketogenic diet reduces seizures in Dravet syndrome. They will investigate two metabolic pathways in a genetic mouse model of Dravet syndrome and use neuroimaging techniques to assess these impacts within the brain. | $150,000 |
Denver, CO PURPOSE: Lymphoblast Cell Lines as a Model to Uncover Metabolic Defects in Dravet Syndrome- Dr. Patel and Dr. Knupp work together on this collaborative project to establish lymphoblast cell lines from the blood of patients with Dravet syndrome and their unaffected siblings. This library of cell lines will then be used to investigate alterations in energy metabolism that may impact patients with Dravet syndrome as well as stand as a future resource for investigations of new drugs, diets, and treatment responses. | $150,000 |
Ann Arbor, MI PURPOSE: Optimizing the Regional Administration of SCN8a-targeting RNAi Therapy- Dr. Yu's project worked to develop an AAV-delivery for a genetic-based therapy targeting the SCN8A gene. While the majority of cases of Dravet syndrome are caused by mutations in SCN1A, Dr. Yu and the Meisler lab have shown that using genetic-based therapies to reduce expression of the SCN8A gene can compensate for loss-of-function SCN1A-mutations that cause Dravet syndrome. | $50,000 |
Over the last fiscal year, we have identified 20 grants that Dravet Syndrome Foundation Inc has recieved totaling $184,528.
Awarding Organization | Amount |
---|---|
Marilyn Lichtman Foundation Wantagh, NY PURPOSE: GENERAL CHARITY | $50,000 |
George & June Block Family Foundation Harwood Heights, IL PURPOSE: GENERAL PURPOSE | $30,000 |
Schwab Charitable Fund San Francisco, CA PURPOSE: PUBLIC, SOCIETAL BENEFIT | $26,450 |
Raymond James Charitable Endowment Fund St Petersberg, FL PURPOSE: GENERAL SUPPORT | $25,000 |
American Online Giving Foundation Inc Newark, DE PURPOSE: GENERAL SUPPORT | $18,037 |
Amazonsmile Foundation Seattle, WA PURPOSE: GENERAL SUPPORT | $7,818 |
Organization Name | Assets | Revenue |
---|---|---|
Partnership Schools New York, NY | $64,379,139 | $24,282,663 |
Feeding Pennsylvania Lemoyne, PA | $10,818,120 | $21,841,545 |
Royal College Of Art Usa Inc New York, NY | $1,933,182 | $14,916,047 |
American Friends Of B Nai Levy Foundation Brooklyn, NY | $493,786 | $13,431,000 |
Rf Catalytic Capital Inc New York, NY | $241,603,034 | $246,273,218 |
University Of Pittsburgh And Upmc Medical And Health Sciences Fdn Pittsburgh, PA | $0 | $12,874,250 |
Freedom Fund Brooklyn, NY | $51,719,352 | $51,201,158 |
American Friends Of Leket Israel Inc Teaneck, NJ | $3,165,709 | $12,922,662 |
Pittsburgh Promise Foundation Pittsburgh, PA | $59,585,111 | $15,082,951 |
Pennsylvania Ems Provider Foundation Harrisburg, PA | $55,116 | $0 |
Student Leadership Network Inc New York, NY | $11,626,545 | $12,224,104 |
The Good Nation Foundation Inc New York, NY | $2,105,948 | $9,558,970 |